This is a preview of subscription content, log in via an institution to check access.
References
McKeage MJ, Raynaud F, Ward J, et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. Journal of Clinical Oncology. 15: 2691–2700, Jul 1997. England. [English]
Fujii H, Sasaki Y, Tamura T, Cooperative Group of JM216 in Japan, et al. A phase I and pharmacokinetic study of the oral platinum analog JM216. 33rd Annual Meeting of the American Society of Clinical Oncology.: 215, 17 May 1997. Japan. [English]
Vouillamoz-Lorenz S, Decosterd LA, Bauer J, et al. A phase I pharmacokinetic study of the oral platinum analog JM216 administered once a day over 14 days. Annals of Oncology. 9 (Suppl 2): 130, 1998 Switzerland. [English]
Sessa C, Minoia C, Ronchi A, Zucchetti M, Bauer J, et al. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Annals of Oncology. 9: 1315–1322, Dec 1998 Switzerland. [English]
Peereboom D, Wood L, Connell C, et al. Phase II trial of oral platinum in hormone refractory prostate cancer. 34th Annual Meeting of the American Society of Clinical Oncology. 17: 314, 16 May 1998. USA. [English]
Judson I, Cerny T, Epelbaum R, Dunlop D, Smyth J, et al. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Annals of Oncology. 8: 604–606, Jun 1997. England. [English]
Harper E, Dang W, Lapidus RG, Garver Jr RI. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clinical Cancer Research. 5: 4242–4248, Dec 1999. USA. [English]
Trudeau M, Stuart G, Hirte H, Drouin P, Plante M, et al. NCIC CTGIND102: a phase II study of the oral platinum compound BMS-182751 in patients with advanced and or recurrent squamous cell carcinoma of the cervix. European Journal of Cancer. 35 (Suppl 4): 235 (plus poster), Sep 1999. Canada. [English]
De Mario MD, Ratain MJ, Vogelzang NJ, et al. Aphase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetatoammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. Cancer Chemotherapy and Pharmacology. 43: 385–388, May 1999. USA. [English]
Kelland LR, McKeage MJ. New platinum agents: a comparison in ovarian cancer. Drugs and Aging. 5: 85–95, Aug 1994. England. [English]
Mohr PJ, Hercules SK, Amorino GP, et al. Enhancement of radiation effects in vivo by the orally active platinum drug JM216. 35th Annual Meeting of the American Society of Clinical Oncology. 18: 454, 15 May 1999. USA. [English]
McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, et al. Aphase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemotherapy and Pharmacology. 36: 451–458, Oct 1995. England. [English]
Fokkema E, Lunenberg J, van Putten JWG, van Rijswijk REN, Weil C, et al. Randomized phase II study of oral JM216 versus intravenous cisplatin in non-small cell lung cancer: preliminary results. 34th Annual Meeting of the American Society of Clinical Oncology. 17: 483, 16 May 1998. Netherlands. [English]
Fokkema E, Groen HJM, Bauer J, Uges DRA, Weil C, et al. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. Journal of Clinical Oncology. 17: 3822–3827, Dec 1999. Netherlands. [English]
Rights and permissions
About this article
Cite this article
Satraplatin. Drugs R&D 3, 67–71 (2002). https://doi.org/10.2165/00126839-200203010-00017
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200203010-00017